Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Razão tacrolimus C:D medida em receptores de transplante renal tratados com medicamentos de liberação prolongada uma vez ao dia (TaC:Drop)

3 de novembro de 2026 atualizado por: Edward Geissler

Ensaio multicêntrico, aberto, randomizado, de dois braços, grupo paralelo, de superioridade para avaliar a biodisponibilidade e praticabilidade de duas formulações de tacrolimus uma vez ao dia, Envarsus® em comparação com Advagraf™, administrado em receptores de transplante renal

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Descrição detalhada

This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.

The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.

Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.

Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.

Tipo de estudo

Intervencional

Inscrição (Real)

322

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aachen, Alemanha, 52074
        • University Hospital Aachen, Department of General, Visceral and Transplant Surgery
      • Berlin, Alemanha, 10117
        • Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
      • Bochum, Alemanha, 44892
        • Knappschaft Clinic, University Hospital Bochum, Department of Surgery
      • Dresden, Alemanha, 01307
        • University Hospital Dresden, Division of Nephrology
      • Hamburg, Alemanha, 20251
        • University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
      • Hanover, Alemanha, 30625
        • Hannover Medical School, Department of General, Visceral and Transplant Surgery
      • Jena, Alemanha, 07747
        • University Hospital Jena, Internal Medicine III, Nephrology
      • Mainz, Alemanha, 55131
        • University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
      • Mannheim, Alemanha, 68167
        • University Hospital Mannheim, Medical Clinic V
      • Munich, Alemanha, 81377
        • LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
      • Münster, Alemanha, 48149
        • University Hospital Münster, Medical Clinic D
      • Regensburg, Alemanha, 93053
        • University Hospital Regensburg, Department of Nephrology
      • Würzburg, Alemanha, 97080
        • University Hospital Würzburg, Medical Clinic I, Department of Nephrology

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Signed and dated written informed consent
  2. Adult (≥18 years old) male or female
  3. Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
  4. ABO blood type compatible with the donor kidney
  5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form

Exclusion Criteria:

  1. Multi-organ transplantation
  2. Any previous solid organ transplantation (other than a first kidney allograft)
  3. For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
  4. Patient and/or donor is positive for active HCV, HBV or HIV infection
  5. History of any malignancy that could not be curatively treated
  6. Ongoing abuse of drugs or alcohol
  7. Signs of advanced liver disease or any signs of liver decompensation
  8. Ongoing uncontrolled systemic infection
  9. Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
  10. Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
  11. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
  12. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
  14. Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
  15. Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
  16. Inability to freely give informed consent (e.g. individuals under legal guardianship)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Envarsus

Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Outros nomes:
  • Envarso
Comparador Ativo: Advagraf

Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Outros nomes:
  • Advagraf

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Prazo: 12 weeks after kidney transplantation

To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory.

12 weeks after kidney transplantation

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proporção de pacientes com níveis mínimos inferiores, dentro ou superiores ao intervalo alvo
Prazo: 4 dias, 14 dias, 28 dias e 12 semanas após o transplante renal
4 dias, 14 dias, 28 dias e 12 semanas após o transplante renal
Nível mínimo médio de tacrolimus e variabilidade interpaciente (intervalo) dos níveis mínimos de tacrolimus
Prazo: 4 dias, 14 dias, 28 dias e 12 semanas após o transplante renal
4 dias, 14 dias, 28 dias e 12 semanas após o transplante renal
Dose diária média de tacrolimus e variabilidade entre pacientes (intervalo) da dose diária de tacrolimus
Prazo: 4 dias, 14 dias, 28 dias e 12 semanas após o transplante renal
4 dias, 14 dias, 28 dias e 12 semanas após o transplante renal
Variabilidade intrapaciente da relação C/D e dose diária
Prazo: Medido ao longo dos pontos de tempo: dia 4, dia 14, dia 28 e semana 12
Medido ao longo dos pontos de tempo: dia 4, dia 14, dia 28 e semana 12
Taxa de incidência de biópsias por causa
Prazo: 12 semanas após o transplante renal
12 semanas após o transplante renal
Taxa de incidência de episódios de rejeição aguda que requerem tratamento
Prazo: 12 semanas após o transplante renal
12 semanas após o transplante renal
Taxa de incidência de episódios resistentes a esteróides de rejeição aguda comprovada por biópsia
Prazo: 12 semanas e 1 ano após o transplante renal
12 semanas e 1 ano após o transplante renal
Incidência de infecção por CMV e BKV (incluindo manifestação em órgãos, se relevante)
Prazo: 12 semanas e 1 ano após o transplante renal
12 semanas e 1 ano após o transplante renal
Incidência, tipo, gravidade e gravidade das reações adversas (RAs)
Prazo: 12 semanas e 3 anos após o transplante renal
12 semanas e 3 anos após o transplante renal
Pressão arterial
Prazo: 12 semanas e 1, 2, 3 anos após o transplante renal
12 semanas e 1, 2, 3 anos após o transplante renal
Incidência de distúrbios gastrointestinais que requerem investigação diagnóstica
Prazo: 12 semanas e 3 anos após o transplante renal
12 semanas e 3 anos após o transplante renal
Recorrência de doença renal primária
Prazo: 12 semanas e 3 anos após o transplante renal
12 semanas e 3 anos após o transplante renal
Incidência de DSA de novo
Prazo: Detectado no primeiro ano após o transplante renal
Detectado no primeiro ano após o transplante renal
Doses e duração do tratamento com glicocorticosteroides
Prazo: 12 semanas e 1, 2, 3 anos após o transplante renal
12 semanas e 1, 2, 3 anos após o transplante renal
Incidência e tempo para estudar a descontinuação do tratamento
Prazo: 3 anos após o transplante renal
3 anos após o transplante renal
Incidência, tempo e motivo da retirada do paciente do estudo
Prazo: 3 anos após o transplante renal
3 anos após o transplante renal
Time to reach the first trough level in target range
Prazo: Time period measured in days, assessed within the first 2 weeks after kidney transplantation

Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading

Time period measured in days, assessed within the first 2 weeks after kidney transplantation
Tacrolimus concentration/dose (C/D) ratio
Prazo: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation

The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site.

4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
Treatment failure rate
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause)

12 weeks and 1, 2, 3 years after kidney transplantation
Time to treatment failure after transplantation
Prazo: Measured until 3 years after kidney transplantation

Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause)

Measured until 3 years after kidney transplantation
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition.

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of graft failure
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation

12 weeks and 1, 2, 3 years after kidney transplantation
Mortality rate
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

Mortality rate measures death from any cause

12 weeks and 1, 2, 3 years after kidney transplantation
Graft function measured by eGFR (estimated glomerular filtration rate)
Prazo: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation

eGFR calculated according to the CKD-EPI formula

4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of delayed graft function
Prazo: Measurable within the first 2 weeks after kidney transplantation

Delayed graft function is defined as the need for more than one episode of dialysis after transplantation

Measurable within the first 2 weeks after kidney transplantation
Incidence rate of primary non-function of the renal allograft
Prazo: Measurable within the first 12 weeks after kidney transplantation

Primary non-function is defined as the necessity for ongoing chronic dialysis

Measurable within the first 12 weeks after kidney transplantation
Incidence of hepatotoxicity
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence of de novo tremor
Prazo: 12 weeks and 3 years after kidney transplantation

Incidence and severity of tremor based on medical assessment by the investigator

12 weeks and 3 years after kidney transplantation
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions

12 weeks and 1, 2, 3 years after kidney transplantation
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Prazo: 12 weeks and 3 years after kidney transplantation

The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients.

12 weeks and 3 years after kidney transplantation
Dose of mycophenolate
Prazo: 12 weeks and 1, 2, 3 years after kidney transplantation

Including both mycophenolate mofetil and mycophenolic acid

12 weeks and 1, 2, 3 years after kidney transplantation

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Bernhard Banas, MD, University Hospital Regensburg

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

9 de março de 2024

Conclusão Primária (Real)

4 de fevereiro de 2026

Conclusão do estudo (Estimado)

1 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de fevereiro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de fevereiro de 2024

Primeira postagem (Real)

20 de fevereiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • TaC:Drop
  • 2023-503531-18-00 (Outro identificador: EUCT Number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever